- Phantom Pharmaceuticals is developing a next-generation stomach acid reducer that would represent the first new mechanism of action in the space in 30 years.
- Phantom's drug, vonoprazan, has already succeeded in multiple Phase 3 trials overseas, which should bode well for its two ongoing US Phase 3 trials.
- Phantom's $1.2 billion market cap will likely prove very cheap if vonoprazan gets approved, given the extremely large market for branded reflux medications.
For further details see:
Phantom Pharmaceuticals Could See Substantial Upside With 2 Upcoming Phase 3 Readouts